Form 4: LVTX Director Noble Cancels Share Options

LAVA Therapeutics Director James Noble cancels 33,390 share options for cash and contingent value rights.

Summary

• James Noble, a Director of LAVA Therapeutics NV (LVTX), reported a change in beneficial ownership.
• 33,390 share options (Right to Buy) with an exercise price of $0.93 were cancelled.
• The cancellation occurred on November 13, 2025, pursuant to a Purchase Agreement dated August 3, 2025, between LAVA Therapeutics NV and XOMA Royalty Corporation.
• In exchange for the cancelled options, Noble received cash and Contingent Value Rights (CVRs).
• The cash component is calculated as the excess of $1.04 over the per share exercise price ($0.93), multiplied by the total number of shares underlying the option.
• Noble also received one CVR per share underlying the in-the-money option.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The director realized a gain on in-the-money options, which is positive for the individual. The transaction itself is a routine disclosure of an insider's change in holdings, part of a pre-existing agreement, so it doesn't indicate significant positive or negative news for the company's operations directly.

Positives

• The options were 'in-the-money' as the exchange value of $1.04 per share exceeded the exercise price of $0.93, indicating a gain for the director.
• The transaction is part of a Purchase Agreement with XOMA Royalty Corporation, which could be a strategic move for the company.

Negatives

• The director no longer holds direct equity upside from these specific share options.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the director's option cancellation as a routine event, potentially positive if it is part of a larger strategic move (Purchase Agreement with XOMA Royalty Corporation).

Key Dates

Recommendation

This Form 4 details a routine insider transaction where a director's in-the-money options were cancelled as part of a pre-existing purchase agreement. It does not provide sufficient information to alter a fundamental investment thesis for LAVA Therapeutics NV. The transaction itself is neutral to slightly positive for the director, but does not offer new insights into the company's operational performance or strategic direction that would warrant a change from a 'hold' position.

Keywords

LAVA Therapeutics, LVTX, Form 4, Insider Transaction, Share Options, Director, Contingent Value Rights, XOMA Royalty Corporation